Effectiveness of Pneumococcal Vaccine among Chronic Respiratory Disease Monks in Priest Hospital


  • Jaruphat Asawaplungkul, M.D.


Chronic respiratory disease, Community-acquired pneumonia, Pneumococcal vaccine


Background : Chronic respiratory disease (CRD) has a higher incidence of community-acquired pneumonia (CAP) infected by Streptococcus pneumonia, the major cause of death. A significant reduction of CAP in the elderly has demonstrated after pneumococcal vaccination, especially when combined with influenza virus vaccination (IVV). However, the effectiveness among CRD patients remain unknown.

Objective : To determine the effectiveness of 13-valent pneumococcal conjugate vaccine (PCV-13) in reduction of CAP among CRD patients.

Method : A retrospective cohort study was conducted among CRD patients from 1st January 2014 to 31st May 2020 at Priest Hospital, Thailand. Patients were divided into the PCV-13 group and the non-PCV-13 group.

Results : Total of 191 patients were enrolled in this study. Among these, 97 patients in the PCV-13 group (with IVV 91 patients, without IVV 6 patients), and 94 patients in the non-PCV-13 group (with IVV 55, without IVV 39 patients). Multivariable analysis showed better reduction of CAP in PCV-13 group (IRR 0.119; 95% CI = 0.018, 0.768, p = 0.025), especially when PCV-13 was given concomittantly with IVV (IRR 0.017; 95% CI = 0.001, 0.298, p = 0.005) comparing to non-vaccinated patients. However, patients in PCV-13 group were not shown the reduction rate of bronchitis (IRR 0.902; 95% CI = 0.503, 1.619, p = 0.731) and exacerbation (IRR 1.335; 95% CI = 0.683, 2.611, p = 0.398).

Conclusion : 13-valent pneumococcal conjugate vaccine was demonstrated to reduce the incidence of community-acquired pneumonia in patients with chronic respiratory disease. The optimal result was found when the influenza vaccine was given concomitantly.


Download data is not yet available.


Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010;35:1209-15.

Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65.

Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZqA, Carter A, et al. Global, regional, and national life expectancy, allcause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1459-544.

World Health Organization. The top 10 causes of death 2016[Internet]. [cited 2020 Aug 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

European Respiratory Society. The European Lung White Book: Respiratory Health and Disease in Europe:European Respiratory Society.[Internet]. 2016 [cited 2020 Jul 20].Available from:https://www.erswhitebook.org/chapters/the-burden-of-lung-disease/.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.

Mullerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis.Respir Med 2012;106:1124-33.

Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C,Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009.Thorax. 2009;64 Suppl 3:iii1-55.

Woodhead M. Community-acquired pneumonia in Europe:causative pathogens and resistance patterns. Eur Respir J Suppl 2002;36: s20-7.

Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1:ofu024.

Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M,O’Brien KL, Team AAPBS, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8:e60273.

Wedzicha JA, Mackay AJ, Singh R. COPD exacerbations: impact and prevention. Breathe 2013;9:434-40.

Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococca lvaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:Cd001390.

Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008;5:52.

Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 2012;102:596-605.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019;5:53.

Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17 Suppl 1:S91-3.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-25.

Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U,Techasaensiri C, Chotpitayasunondh T, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine 2019;37:4551-60.



How to Cite

จารุภัทร อัศวพลังกูล พ.บ. Effectiveness of Pneumococcal Vaccine among Chronic Respiratory Disease Monks in Priest Hospital. j dept med ser [Internet]. 2021 Mar. 10 [cited 2022 Aug. 14];45(4):138-47. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/249798



Original Article